This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Month Names:$MonthNames

Day Names:$dayNameShort

Popup

Apr 2023

While INCS are recommended by guidelines as a first-line therapy for children with moderate-severe AR, its use may be limited by the potential for adverse events.1-4 To evaluate the safety profile of INCS, experts reviewed 20 randomised clinical trials conducted on children with AR and treated with INCS.4 According to the experts’ assessment, INCS are generally tolerable at recommended doses in the paediatric populations.‡‡4 While the experts advised caution for those with ocular disorders, 2nd generation INCS display a favourable pharmacokinetic profile and minimal systematic adverse effects.‡‡4
 

Read more

References:

  1. Seidman MD et al. Otolaryngol Head Neck Surg 2015;152:S1–43.
  2. Scadding GK et al. Clin Exp Allergy 2017;47:856–89.
  3. Scadding GK et al. Front Allergy 2021;2:706589.
  4. Zhang M et al. Expert Opin Drug Saf 2022;21:931–8.

To report an Adverse Event, please contact the toll free line 0800 CALL GSK (0800 2255 475) or send an email